Cargando…

Genomic and Immune Profiling of a Patient With Triple-Negative Breast Cancer That Progressed During Neoadjuvant Chemotherapy Plus PD-L1 Blockade

Detalles Bibliográficos
Autores principales:	Casadevall, David, Li, Xiaotong, Powles, Ryan L., Wali, Vikram B., Buza, Natalia, Pelekanou, Vasiliki, Dhawan, Arjun, Foldi, Julia, Szekely, Borbala, Lopez-Giraldez, Francesc, Hatzis, Christos, Pusztai, Lajos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450962/ https://www.ncbi.nlm.nih.gov/pubmed/32914041 http://dx.doi.org/10.1200/PO.18.00335

Ejemplares similares

Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer
por: Wali, Vikram B., et al.
Publicado: (2019)

Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial
por: Li, Xiaotong, et al.
Publicado: (2019)

Treatment scheduling effects on the evolution of drug resistance in heterogeneous cancer cell populations
por: Patwardhan, Gauri A., et al.
Publicado: (2021)

Multi-Omics Investigation of Innate Navitoclax Resistance in Triple-Negative Breast Cancer Cells
por: Marczyk, Michal, et al.
Publicado: (2020)

Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
por: Foldi, Julia, et al.
Publicado: (2021)

Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis
por: Jiang, Tingting, et al.
Publicado: (2016)

Statistical measures of transcriptional diversity capture genomic heterogeneity of cancer
por: Jiang, Tingting, et al.
Publicado: (2014)

Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance
por: Pelekanou, Vasiliki, et al.
Publicado: (2017)

Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
por: Foldi, Julia, et al.
Publicado: (2022)

Erratum to: Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance
por: Pelekanou, Vasiliki, et al.
Publicado: (2017)

CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers
por: Pelekanou, Vasiliki, et al.
Publicado: (2018)

Functional polymorphisms in cancer
por: Agarwal, Divyansh, et al.
Publicado: (2015)

Immunological Differences Between Immune-Rich Estrogen Receptor–Positive and Immune-Rich Triple-Negative Breast Cancers
por: O’Meara, Tess, et al.
Publicado: (2020)

Characterization of DNA variants in the human kinome in breast cancer
por: Agarwal, Divyansh, et al.
Publicado: (2015)

An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes
por: Győrffy, Balázs, et al.
Publicado: (2018)

Reliability of Whole-Exome Sequencing for Assessing Intratumor Genetic Heterogeneity
por: Shi, Weiwei, et al.
Publicado: (2018)

Functional germline variants as potential co-oncogenes
por: Agarwal, Divyansh, et al.
Publicado: (2017)

Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer
por: Marczyk, Michal, et al.
Publicado: (2022)

Multigene prognostic tests in breast cancer: past, present, future
por: Győrffy, Balázs, et al.
Publicado: (2015)

A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients
por: Pongor, Lőrinc, et al.
Publicado: (2015)

Evaluation of zero counts to better understand the discrepancies between bulk and single-cell RNA-Seq platforms
por: Zyla, Joanna, et al.
Publicado: (2023)

Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancers
por: Li, Xiaotong, et al.
Publicado: (2021)

A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer
por: Iwase, Toshiaki, et al.
Publicado: (2021)

Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial
por: Fanucci, Kristina A., et al.
Publicado: (2023)

Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a case–control study
por: Yaghoobi, Vesal, et al.
Publicado: (2021)

Neoadjuvant programmed death-1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma
por: Yang, Guozhen, et al.
Publicado: (2021)

Case Report: Neoadjuvant PD-1 Blockade Plus Concurrent Chemoradiotherapy in Unresectable Locally Advanced Gastric Cancer Patients
por: Wei, Jia, et al.
Publicado: (2021)

Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer
por: Foldi, Julia, et al.
Publicado: (2023)

Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer
por: Kunst, Natalia, et al.
Publicado: (2020)

Gene expression profiling of breast cancer
por: Pusztai, Lajos
Publicado: (2009)

Increased epigenetic age in normal breast tissue from luminal breast cancer patients
por: Hofstatter, Erin W., et al.
Publicado: (2018)

Predictive factors of neoadjuvant immune checkpoint blockade in melanoma
por: Sarver, Melissa, et al.
Publicado: (2021)

Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer
por: Mani, Nikita L., et al.
Publicado: (2016)

Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic
por: Park, Ko Un, et al.
Publicado: (2021)

Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma
por: Amaria, Rodabe N., et al.
Publicado: (2018)

Predicting prognosis of breast cancer with gene signatures: are we lost in a sea of data?
por: Iwamoto, Takayuki, et al.
Publicado: (2010)

Molecular profiling contributes more than routine histology and immonohistochemistry to breast cancer diagnostics
por: Shiang, Christine, et al.
Publicado: (2010)

Germline variant burden in cancer genes correlates with age at diagnosis and somatic mutation burden
por: Qing, Tao, et al.
Publicado: (2020)

The impact of RNA extraction method on accurate RNA sequencing from formalin-fixed paraffin-embedded tissues
por: Marczyk, Michal, et al.
Publicado: (2019)

Neoadjuvant Dose-Dense Gemcitabine plus Docetaxel and Vinorelbine plus Epirubicin for Operable Breast Cancer: Improved Prognosis in Triple-Negative Tumors
por: Medioni, Jacques, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_vo1bohocfol8tqnp15u6br80ol